A randomized phase II study of preoperative Herceptin [trastuzumab]/Navelbine [vinorelbine] versus Taxotere [docetaxel]/Carboplatin/Herceptin in early stage, HER-2 positive breast cancer.

Trial Profile

A randomized phase II study of preoperative Herceptin [trastuzumab]/Navelbine [vinorelbine] versus Taxotere [docetaxel]/Carboplatin/Herceptin in early stage, HER-2 positive breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Docetaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary) ; Carboplatin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Feb 2016 Pooled results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 04 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top